Literature DB >> 26407752

Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Lauranne A A P Derikx1, Loes H C Nissen1, Lisa J T Smits1, Bo Shen2, Frank Hoentjen3.   

Abstract

BACKGROUND & AIMS: Colorectal neoplasia can still develop after colectomy for inflammatory bowel disease. However, data on this risk are scare, and there have been few conclusive findings, so no evidence-based recommendations have been made for postoperative surveillance. We conducted a systematic review and meta-analysis to determine the prevalence and incidence of and risk factors for neoplasia in patients with inflammatory bowel disease who have undergone colectomy, including the permanent-end ileostomy and rectal stump, ileorectal anastomosis (IRA), and ileal pouch-anal anastomosis (IPAA) procedures.
METHODS: We searched PubMed, Embase, Web of Science, and Cochrane Library through May 2014 to identify studies that reported prevalence or incidence of colorectal neoplasia after colectomy or specifically assessed risk factors for neoplasia development. Studies were selected, quality was assessed, and data were extracted by 2 independent researchers.
RESULTS: We calculated colorectal cancer (CRC) prevalence values from 13 studies of patients who underwent rectal stump surgery, 35 studies of IRA, and 33 studies of IPAA. Significantly higher proportions of patients in the rectal stump group (2.1%; 95% confidence interval [CI], 1.3%-3.0%) and in the IRA group (2.4%; 95% CI, 1.7%-3.0%) developed CRC than in the IPAA group (0.5%; 95% CI, 0.3%-0.6%); the odds ratio (OR) for CRC in the rectal stump or IRA groups compared with the IPAA group was 6.4 (95% CI, 4.3-9.5). A history of CRC was the most important risk factor for development of CRC after colectomy (OR for patients receiving IRA, 12.8; 95% CI, 3.31-49.2 and OR for patients receiving IPAA, 15.0; 95% CI, 6.6-34.5).
CONCLUSIONS: In a meta-analysis of published studies, we found the prevalence and incidence of CRC after colectomy to be less than 3%; in patients receiving IPAA it was less than 1%. Factors that increased risk of cancer development after colectomy included the presence of a residual rectum and a history of CRC. These findings could aid in development of individualized strategies for post-surgery surveillance.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Crohn’s Disease; Dysplasia; Epidemiology; Ulcerative Colitis

Mesh:

Year:  2015        PMID: 26407752     DOI: 10.1016/j.cgh.2015.08.042

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  12 in total

Review 1.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease.

Authors:  G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-14       Impact factor: 3.781

Review 2.  Colon Cancer: Inflammation-Associated Cancer.

Authors:  Sherief Shawki; Jean Ashburn; Steven A Signs; Emina Huang
Journal:  Surg Oncol Clin N Am       Date:  2017-12-15       Impact factor: 3.495

Review 3.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis.

Authors:  G Pellino; D S Keller; G M Sampietro; M Carvello; V Celentano; C Coco; F Colombo; A Geccherle; G Luglio; M Rottoli; M Scarpa; G Sciaudone; G Sica; L Sofo; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-02       Impact factor: 3.781

4.  A contemporary series of surgical outcomes following subtotal colectomy and/or completion proctectomy for management of inflammatory bowel disease.

Authors:  Lucy Burns; Michael E Kelly; Maria Whelan; James O'Riordan; Paul Neary; Dara O Kavanagh
Journal:  Ir J Med Sci       Date:  2022-01-17       Impact factor: 1.568

5.  Increased Colorectal Neoplasia Risk in Patients with Inflammatory Bowel Disease and Serrated Polyps with Dysplasia.

Authors:  Frank Hoentjen; Michiel E de Jong; Iris D Nagtegaal; Shoko Vos; Rachel S van der Post; Yasmijn van Herwaarden; Lauranne A A P Derikx
Journal:  Dig Dis Sci       Date:  2022-04-05       Impact factor: 3.199

Review 6.  Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.

Authors:  Shailja C Shah; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2021-10-29       Impact factor: 22.682

7.  Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.

Authors:  Michiel E De Jong; Sanne B Van Tilburg; Loes H C Nissen; Wietske Kievit; Iris D Nagtegaal; Carmen S Horjus; Tessa E H Römkens; Joost P H Drenth; Frank Hoentjen; Lauranne A A P Derikx
Journal:  J Crohns Colitis       Date:  2019-12-10       Impact factor: 9.071

8.  Subtotal colectomy in ulcerative colitis-long term considerations for the rectal stump.

Authors:  Orla Hennessy; Laurence Egan; Myles Joyce
Journal:  World J Gastrointest Surg       Date:  2021-02-27

Review 9.  Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer.

Authors:  Aranzazu Jauregui-Amezaga; Séverine Vermeire; Hans Prenen
Journal:  Ann Gastroenterol       Date:  2016 Apr-Jun

10.  No Increased Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease and Postinflammatory Polyps.

Authors:  Michiel E de Jong; Veerle E L M Gillis; Lauranne A A P Derikx; Frank Hoentjen
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.